Company* |
Company* (Country; |
Type/ |
Terms/ |
| |||
Adherex Technologies Inc. (Canada; TSE:AHX) |
Cadherin Biomedical Inc.* |
Adherex agreed to acquire noncancer cadherin-based intellectual property from CBI |
Adherex will pay $1M by issuing up to 2.2M shares of stock, and a royalty rate of 2%; the deal requires approval from CBI shareholders (12/10) |
|
|||
Aeres Biomedical Ltd.* (UK) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Agreement under which Aeres will humanize a vascular-targeting antibody |
Peregrine will provide a murine antibody for humanization by Aeres; terms were not disclosed (12/11) |
|
|||
Affymetrix Inc. (AFFX) |
NuGEN Technologies Inc.* |
Collaboration to develop NuGEN's Whole Transcript Amplification system for use with Affymetrix GeneChip technology |
They intend to develop a new target amplification method to support the next generation of GeneChip arrays; terms were not disclosed (12/10) |
|
|||
Affymetrix Inc. (AFFX) |
Arcturus Bioscience Inc.* |
Collaboration to develop tools for gene expression analysis on paraffin-embedded clinical biopsy samples |
The companies will use Paradise reagents from Arcturus with a new custom array from Affymetrix (12/4) |
|
|||
Agenix Ltd. (Australia; ASX:AGX) |
Biosite Inc. (BSTE) |
License agreement under which Biosite licensed rights to D-dimer |
Biosite intends to incorporate the 3B6 antibody from AGEN, a subsidiary, of Agenix, specific for D-dimer, into a diagnostic to identify causes of shortness of breath; terms were not disclosed (11/26) |
|
|||
Alexion Pharmaceuticals Inc. (ALXN) |
XOMA Ltd. (XOMA) |
Collaboration for development of a human c-MPL agonist antibody to treat chemotherapy-induced thrombocytopenia; Alexion discovered the preclinical compound |
The companies will jointly develop and commercialize the compound, sharing expenses and revenues on a 70-30 split, with Alexion having the larger share; Alexion gets initial payments and a potential milestone, and XOMA is entitled to royalties and milestones (12/18) |
|
|||
Archemix Corp.* |
Regado Biosciences* |
License agreement granting Regado rights to develop antidote-controlled aptamer therapeutics |
The license relates to Archemix's SELEX patent portfolio; Regado is using the technology to develop drugs for thrombosis (11/17) |
|
|||
Avalon Pharmaceuticals Inc.* |
Medarex Inc. (MEDX) |
Collaboration on development of antibody products using Avalon targets and Medarex technology |
The companies will shares the costs and responsibilities of development, and jointly commercialize resulting products (10/30) |
|
|||
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
Peregrine Pharmaceuticals Inc. (PPHM) |
License agreement for an antibody Avanir produced for a cancer target in Peregrine's vascular-targeting program |
Avanir received a license fee and could get a milestone payment along with royalties on sales; terms were not disclosed (12/10) |
|
|||
Bavarian Nordic A/S* (Denmark) |
Pharmexa A/S* (Denmark) |
Collaboration to test Bavarian's MVA-BN vector technology in combination with Pharmexa's HER-2 DNA AutoVac vaccine |
The companies expect to start Phase I/II trials in 18 months in that program, and test other combinations in breast cancer patients; terms were not disclosed (10/30) |
|
|||
Berna Biotech Ltd. (Switzerland; SWX:BBIN) |
Dynavax Technologies Corp.* |
License and supply agreement under which Dynavax gets worldwide, nonexclusive rights to use Berna's hepatitis B surface antigen, HBsAg |
Dyanavax will incorporate the technology in ISS development programs targeting HBV; Berna will supply the antigen and Dynavax will commercialize resulting products exclusively; terms were not disclosed (11/3) |
|
|||
Biogen Idec Inc. (BIIB) |
Therion Biologics Corp.* |
Therion licensed patent rights relating to lymphocyte function associated with antigen-3 |
Therion got a nonexclusive license for oncology products incorporating the LFA-3 co-stimulatory molecule; Therion is paying an up-front fee and potential milestones and royalties (12/15) |
|
|||
Bruker Daltonics Inc. (unit of Bruker Biosciences Corp; BRKR) |
SurroMed Inc.* |
Parternship that includes purchase of Bruker mass spectrometers for use by SurroMed |
The deal includes a collaboration on development of software and sample fractionation products; terms were not disclosed (12/1) |
|
|||
CeMines Inc.* |
Chemicon International Inc. (unit of Serologicals Corp; SERO) |
Exclusive five-year licensing agreement under which Chemicon has access to 170 CeMines antibodies |
Chemicon will use the antibodies to broaden its offering of transcription factor reagents for cancer and cell biology researchers; Chemicon has an option to get access to additional antibodies for the life of the deal; terms were not disclosed (10/30) |
|
|||
Chemical Diversity Labs Inc.* |
ESBATech AG* (Switzerland) |
CDL is supplying ESBATech a maximally diverse library for screening |
ESBATech will screen the library in its yeast-based system and the University of Zurich will use an in silico approach; terms were not disclosed (12/15) |
|
|||
Chemical Diversity Labs Inc.* |
Sienabiotech SpA* (Italy) |
Research collaboration under which Sienabiotech will screen the aspartyl protease-focused library provided by CDL |
Terms of the deal were not disclosed (12/2) |
|
|||
Chiron Corp. (CHIR) |
Vertex Pharmaceuticals Inc. (VRTX) |
Vertex licensed nonexclusive rights to research and develop drugs against certain hepatitis C targets |
Also, Chiron was granted limited rights to review Vertex's HCV drug VX-950 for potential licensing; the companies settled patent litigation initiated by Chiron in the area of hepatitis C technology; terms of the various deals were not disclosed (11/7) |
|
|||
Chiron Corp. (CHIR) |
Rigel Pharmaceuticals Inc. (RIGL) |
Rigel licensed nonexclusive rights to discover and develop small-molecule therapeutics against certain hepatitis C targets |
Financial and other terms of the deal were not disclosed (11/3) |
|
|||
Collegium Pharmaceuticals Inc.* |
Endo Pharmaceuticals Inc. (ENDP) |
Development and licensing deal for pain products with abuse- deterrent properties |
Collegium will apply its DETERx technology for new fomulations of drugs; Endo is making an up-front payment and will pay milestones and royalties if a product results (12/3) |
|
|||
Coley Pharmaceutical Group Inc.* |
Chiron Corp. (CHIR) |
Chiron licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccine candidates |
Chiron got nonexclusive rights to use the CpG adjuvant in infectious disease vaccines in exchange for up-front license fees and development milestones, as well as royalties on sales (12/23) |
|
|||
CPEC Ltd. (venture of Incara Pharmaceuticals Corp.: INCR; and Indevus Pharmaceuticals Inc.: IDEV) |
ARCA Discovery Inc.* |
ARCA licensed the beta-blocker bucindolol; the drug's development in heart failure was stopped in 1999 |
ARCA licensed the drug after examining trial data and noting a genetic marker that correlates with nonresponders; it would pay CPEC milestones and royalty payments (11/21) |
|
|||
Crucell NV (the Netherlands; CRXL) |
Progenics Pharmaceuticals Inc. (PGNX) |
Crucell will develop a cell line for production of a recombinant protein for Progenics |
The deal involves Crucell's PER.C6 technology; Crucell is eligible for undisclosed milestone payments (12/8) |
|
|||
Cytopia Pty. Ltd. (Australia; subsidiary of Medica Holdings Ltd.) |
Myomatrix Therapeutics LLC |
Collaboration on developing drugs to treat cardiovascular disorders by inhibiting a kinase target |
Each company has technology in the area; they will jointly fund the research program, first targeting an orphan disease, then heart disease and hypertension (12/15) |
|
|||
Cyto Pulse Sciences Inc.* |
Medarex Inc. (MEDX) |
Agreement giving Medarex certain exclusive rights to use Cyto Pulse's electrofusion technology to derive hybridomas for generating human antibody producing cells |
The hybridomas will be derived from the Medarex UltiMAb System; terms of the deal were not disclosed (12/18) |
|
|||
Dharmacon Inc.* |
Akceli Inc.* |
Research collaboration to study combination of Dharmacon's siRNA-mediated gene silencing and Akceli's whole-cell reverse transfection |
Akceli will carry out experiments, and the companies will use results to improve their products; they also intend to develop improved methods for transfection optimization (11/3) |
|
|||
DiagnoCure Pharmaceuticals Inc.* |
Gen-Probe Inc. (GPRO) |
License and collaboration deal in which they will develop a urine test to detect a new genetic marker for prostate cancer |
Gen-Probe would market the test that detects the PCA3 gene; Gen-Probe is paying $3M up front and up to $7.5M over three years, and DiagnoCure would get royalties of 8% or 16%, depending on sales levels (11/20) |
|
|||
Feminique Corp. (OTC BB:FEMQQ) |
Targent Inc.* |
Targent acquired an oral cytotoxic drug, dibromodulcitol, from Feminique |
Terms were not disclosed (12/11) |
|
|||
Genaissance Inc. (GNSC) |
Sciona Ltd.* (UK) |
Genaissance licensed its HAP technology to support product development work at Sciona |
Genaissance is getting a 30% stake in Sciona as part of the deal, and would get royalties on sales related to its technology (11/18) |
|
|||
Genome BioSciences Inc.* |
Chemicon International Inc. (division of Serologicals Corp.; SERO) |
Exclusive license agreement for Genome BioSciences' Positive-Positive Selection gene targeting technology |
Chemicon gained exclusive rights to use the technology for generating genetically modified cell lines and mice and to sub- license the technology; terms were not disclosed (11/18) |
|
|||
GlycoFi Inc.* |
Biogen Idec Inc. (BIIB) |
Joint research study to evaluate GlycoFi's humanized yeast platform for production of an undisclosed Biogen Idec protein |
Biogen Idec will provide support for the study of GlycoFi's expression technology to pro- duce glycoproteins; terms were not disclosed (11/10) |
|
|||
Hemosol Inc. (Canada; HMSL) |
ProMetic Life Sciences Inc. (Canada; TSE:PLI) |
Hemosol in-licensed plasma separation technology developed by ProMetic and the American Red Cross |
Hemosol gained a North American license to Cascade technology in exchange for 2M shares of stock and license fees of $16.5M over four years (12/4) |
|
|||
Icon Genetics AG* (Germany) |
Novoplant GmbH* (Germany) |
License agreement giving Novoplant access to Icon's Transgene Operating Systems for manufacturing immune-response proteins in plants |
The license is expected to help Novoplant develop products for animal health; terms were not disclosed (11/13) |
|
|||
Ingenium Pharmaceuticals AG* (Germany) |
Molecular Engines Laboratories SA* (France) |
Agreement under which MEL gets access to Ingenium's genetic mouse model related to tumor reversion |
MEL gets exclusive rights to the technology on the TSAP6 model; terms were not disclosed (10/28) |
|
|||
Ingenuity Systems* |
SurroMed Inc.* |
License to Ingenuity's Pathway Analysis application for biological research |
Terms were not disclosed (12/8) |
|
|||
Inproteo* |
Pierce Biotechnology Inc.* |
License to "Smith" patent for supply of research reagents and products |
Pierce licensed rights to the fusion protein purification technique; terms were not disclosed (10/29) |
|
|||
Interleukin Genetics Inc. (OTC BB:ILGN) |
Molecular SkinCare Ltd.* (UK) |
Interleukin granted Molecular SkinCare and Asterion Ltd. rights to undisclosed technology |
Interleukin gained a 5% equity stake in Molecular SkinCare as part of the deal; Asterion is an affilate of the University of Sheffield, which had licensed the technology to Interleukin (11/4) |
|
|||
Kalypsys Inc.* |
CV Therapeutics Inc. (CVTX) |
Collaboration to develop drugs for cardiovascular diseases |
CV is providing assays and Kalypsys is developing screens and will optimize leads; Kalypsys is getting undisclosed up-front, research and equity funding; it also could get milestone payments and has an option to co-fund and co-develop resulting drugs (11/17) |
|
|||
KuDOS Pharmaceuticals* (UK) |
Novacea Inc.* |
Novacea licensed from KuDOS North American rights to AQ4N, a hypoxic cell-activated agent for cancer |
Novacea gained rights in all indications in exchange for undisclosed milestone and royalty payments; companies will work together to coordinate worldwide development (12/11) |
|
|||
MacroGenics Inc.* |
Genzyme Corp. (GENZ) |
Partnership to develop therapies for immune-mediated diseases |
They will work to advance MacroGenics' preclinical program targeting the Fc receptor CD16; Genzyme is making a $5M equity investment in MacroGenics, and the companies will jointly fund the program and split resulting profits (10/29) |
|
|||
Maxim Pharmaceuticals Inc. (MAXM) |
Myriad Genetics Inc. (MYGN) |
License deal under which Myriad gets exclusive rights to the MX90745 series of apoptosis- inducing compounds for cancer |
Maxim will receive up to $27M in license fees, research support and milestone payments, as well as royalties on any sales (12/2) |
|
|||
Micrologix Biotech Inc. (Canada; TSE:MBI) |
Spring Bank Technologies Inc.* |
Spring Bank licensed worldwide rights to MBI-1313, a nucleotide analogue being developed for hepatitis B virus infections |
Micrologix will get up to $3.5M in milestone payments, royalties on sales and an equity position in Spring Bank; Spring Bank got a $2.6M grant from the NIH as part of the deal to advance the compound (12/9) |
|
|||
Miikana Therapeutics Inc.* |
NovImmune SA* (Switzerland) |
Collaboration to develop fully human antibody-based drugs for cancer and immune diseases |
The companies are combining efforts in a 50-50 sharing of costs and profits, using Miikana's targets and NovImmune's antibody expertise (10/4) |
|
|||
Mixture Sciences Inc.* |
Mpex Pharmaceuticals Inc.* |
Research collaboration using Mixture's combinatorial libraries to identify antibacterial compounds for Mpex to develop |
Terms were not disclosed (11/20) |
|
|||
Molecular Probes Inc. (subsidiary of Invitrogen Corp.; IVGN) |
Chemicon International Inc. (unit of Serologicals Corp; SERO) |
Licensing agreement under which Chemicon gets rights to fluorophores for labeling biologically active molecules |
The deal includes Alexa Fluor and tandem conjugate technologies from Molecular Probes; terms were not disclosed (10/29) |
|
|||
Neose Technologies Inc. (NTEC) (Germany) |
Rentschler Biotechnologie GmbH & Co. KG* material |
Collaboration under which Neose will develop a therapeutic protein using Rentschler |
Rentschler has an option to co-develop the resulting protein; terms were not disclosed (10/27) |
|
|||
Onyx Pharmaceuticals Inc. (ONXX) |
Sangamo BioScience Inc. (SGMO) |
Sangamo licensed rights to Onyx's oncolytic adenovirus vector technology |
Sangamo got worldwide exclusive rights to all therapeutics using an armed therapeutic virus that encodes a zinc finger DNA-binding protein transcription factor; Onxy is eligible to receive milestone and royalty payments (12/17) |
|
|||
Orphan Medical Inc. (ORPH) |
Celltech Group plc (UK; LSE:CCH) |
License for European rights to Orphan Medical's Xyrem |
Celltech plans to file for approval of Xyrem for cataplexy in early 2004; Celltech paid $2.5M up front and could pay up to $13M in development and sales milestones, as well as royalties on sales (10/30) |
|
|||
Plexxikon Inc.* |
Phenomix Corp.* |
Collaboration to develop a series of small molecules that inhibit the protein kinase c-Kit for treating various diseases |
Plexxikon will apply its discovery platform to create inhibitors, and Phenomix will evaluate the leads; they can develop resulting products alone or jointly, and intend to partner product candidates (11/20) |
|
|||
PreAnalytiX GmbH (Switzerland; venture of Qiagen NV and Becton, Dickinson & Co.) |
Affymetrix Inc. (AFFX) |
Collaboration to optimize the PreAnalytiX PAXgene Blood RNA System for use with Affymetrix GeneChip microarray technology |
A goal is to improve gene expression profile results on RNA extracted from whole blood (10/31) |
|
|||
Qiagen NV (the Netherlands; QGENF) |
Artus GmbH* (Germany) |
Agreement under which Artus will integrate Qiagen's nucleic acid sample preparation products in its diagnostic systems |
The products will be used in the detection of various infectious diseases; terms were not disclosed (12/10) |
|
|||
Qiagen NV (the Netherlands; QGENF) |
Affymetrix Inc. (AFFX) |
Collaboration to optimize Qiagen siRNA-mediated gene silencing using Affymetrix GeneChip microarray technology |
The goal is to develop procedures that can be standarized to analyze effects on a genome-wide basis (10/31) |
|
|||
Scancell Ltd.* (UK) |
Onyvax Ltd.* (UK) |
Agreement on development of Scancell's ImmunoBody cancer vaccine technology |
As part of the deal, Onyvax got a non-exclusive license to develop the technology; details were not disclosed (12/12) |
|
|||
Scynexis Europe Ltd.* (UK) |
GeneCare Research Institute Co. Ltd.* (Japan) |
Scynexis will provide a range of services to support development of anti-inflammatory drugs by GeneCare |
Scynexis' HEOS system will be used to develop high-purity compound libraries for GeneCare; terms were not disclosed (12/8) |
|
|||
SemBioSys Genetics Inc.* (Canada) |
Martek Biosciences Corp. (MRTK) |
Agreement to co-develop value-added specialty oil products with pharmaceutical and nutraceutical applications |
SemBioSys will use its technologies to develop plant-based DHA products for Martek in exchange for up to $10M in research and milestone payments, as well as royalties on product sales (12/17) |
|
|||
Structural GenomiX Inc.* |
UroGene SA* (France) |
Collaboration for discovery and development of drugs for urological cancers |
Companies will jointly develop small-molecule inhibitors; SGX would have rights to resulting products in North America and UroGene in Europe (12/16) |
|
|||
3rd Millennium Inc.* |
CytRx Corp. (CYTR) |
Partnership to implement a computing platform for RNAi- based development programs focused on Type II diabetes and obesity |
CytRx subsidiary Araios Inc. will use the system to generate libraries of compounds targeting those diseases; terms were not disclosed (11/21) |
|
|||
Tripos Inc. (TRPS) |
Biovitrum AB* (Sweden) |
Research program to develop software enabling improved tools for drug discovery |
The informatics project is to enhance the GASP software tool; terms were not disclosed (12/8) |
|
|||
YM BioSciences Inc. (Canada; TSE:YM) |
Oncoscience AG* (Germany) |
Oncoscience licensed European rights to cancer drug TheraCIM hR3, an EGFR antibody |
YM will receive at least $30M as a share of sublicensing fees and as a premium royalty on initial sales, as well as a royalty on sales (11/12) |
|
|||
| |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. |